An advantage of TIM3 inhibition is the selective expression of TIM3 on intratumoral T cells, reducing the unwanted effects on T-cell responses outside of the tumor that are often reported after anti-PD1 or anti-CTLA4 treatment [25]. The gene discussed is HAVCR2; the disease is neoplasm.